1910 Genetics Receives NIH Phase I STTR Grant for Discovery of Novel Non-Opioid Drugs for Chronic Pain
Retrieved on:
Thursday, September 30, 2021
Biotechnology, Technology, White House, Federal Government, Health, Pharmaceutical, Mental Health, Research, Software, Genetics, Public Policy, Government, Science, Drug, Infection, Probability, Initiative, Chronic pain, Artificial intelligence, Research, National, Pain management, NINDS, Patient, National Institute of Neurological Disorders and Stroke, AI, Drug design, Program, Lists of diseases, Technology, National Institute, Drug development, Genetics, Drug discovery, NIH, Lead, Neuroscience, STTR, Machine learning, Immunology, Pharmaceutical industry, the NIH HEAL Initiative, 1910 Genetics, THE NIH HEAL INITIATIVE, 1910 GENETICS
Chronic pain, which affects 50 million Americans, is a serious health problem and a key underlying cause of the opioid crisis.
Key Points:
- Chronic pain, which affects 50 million Americans, is a serious health problem and a key underlying cause of the opioid crisis.
- Opioids, commonly prescribed by clinicians to help patients manage chronic pain, pose life-threatening risk of misuse and abuse, addiction and overdose.
- To date, there are no therapeutic alternatives to opioids for treating chronic pain.
- 1910 Genetics therapeutic area-agnostic, end-to-end technology powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization.